ProShares Ultra NASDAQ Biotechnology
19 hedge funds and large institutions have $2.55M invested in ProShares Ultra NASDAQ Biotechnology in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Holders
19
Holding in Top 10
–
Calls
$322K
Puts
–
Top Buyers
| 1 | +$462K | |
| 2 | +$307K | |
| 3 | +$238K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$48K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$29.8K |
Top Sellers
| 1 | -$366K | |
| 2 | -$122K | |
| 3 | -$14.5K | |
| 4 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
-$11.9K |
| 5 |
Morgan Stanley
New York
|
-$8.61K |
